GEN Exclusives

More »

GEN News Highlights

More »
Aug 10, 2009

Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics

  • Warnex Medical Laboratories signed an exclusive distribution agreement in Canada for three currently available tests from Rosetta Genomics. Samples will be sent from Canada to Rosetta Genomics’ Philadelphia-based CLIA-certified laboratory for analysis.

    Warnex will distribute miRview™ mets, which identifies the primary tumor site in patients presenting with metastatic cancer and those with cancer of unknown primary. miRview™ squamous, which differentiates squamous from nonsquamous, non-small-cell lung cancer, is also included in the agreement. Finally, Warnex will distribute miRview™ meso, which distinguishes mesothelioma from other carcinomas in the lung.

    “This agreement joins our existing contracts with Prometheus Laboratories in the U.S. and with Teva Pharmaceutical in Israel and Turkey,” notes Ronen Tamir, chief commercialization officer at Rosetta Genomics.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?